Correction from Earlier Post

Hey Friends,

I want to correct an error in my earlier Note. I have been working on this post all day, but also dealing with one of our children who is very sick with pneumonia. When I went to post the article, I had posted an earlier version where I had been crossed up with a different study I had been looking at from last year. This doesn’t change the tone or purpose of the article, but some of the data within the publication and the publication I sourced were incorrect.

Here’s the corrected information:

The study, published in Pubmed and available here, looked at compounded versions of semaglutide, tirzepatide, and liraglutide. Researchers looked at around 700 patients in the FAERS database and found higher rates of adverse events vs. branded forms, notably higher rates of improper dosing and hospitalizations. Over 80,000 reports exist in FAERS for GLP-1 medications, and even though 700 represents a very small sample of the total data available, some of what they found is real cause for concern.

Thanks for your understanding, and I appreciate your attention to this update!